Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Vivani Medical, Inc.
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
November 13, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
October 22, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
September 26, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
September 23, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
September 04, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
July 11, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
June 13, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
May 28, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Present at TIDES Conference 2024
May 09, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 26, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
March 06, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
March 01, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
February 28, 2024
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
November 14, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Present at BIO Investor Forum
October 16, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Present at the Boulder Peptide Symposium
September 07, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
September 05, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
August 14, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
July 11, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 14, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Reports First Quarter Financial Results and Provides Business Update
May 15, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
April 04, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 31, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
March 21, 2023
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
November 14, 2022
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Medical to Present at the ThinkEquity Investor Conference
October 17, 2022
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
VANI
Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)
August 31, 2022
From
Vivani Medical, Inc.
Via
Business Wire
Tickers
EYES
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.